1425.6000 -47.00 (-3.19%)
NSE Dec 16, 2025 15:31 PM
Volume: 32,756
 

1425.60
-3.19%
ICICI Securities Limited
In FY23, Tatva Chintan (TATVA) earnings were hurt from a downcycle in its SDA business, which should resume growing FY24 onwards. The addition of a significant new customer to its SDA has the potential to propel growth in the near future. PASC segment will likely reap the benefit of products under qualification and long-term growth on the back of a robust pipeline and cleaner chemistry positioning.
Number of FII/FPI investors increased from 19 to 31 in Sep 2025 qtr.
More from Tatva Chintan Pharma Chem Ltd.
Recommended